TIDMVLG

RNS Number : 1206J

Venture Life Group PLC

07 September 2016

7 September 2016

Venture Life Group plc

("Venture Life" or the "Group")

Notice of Interim Results

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, will announce its Interim Results for the six months ended 30 June 2016 on 21 September 2016.

A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Wednesday 21 September 2016.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email venturelife@walbrookpr.com.

For further information, please contact:

 
 Venture Life Group PLC                                        +44 (0) 1344 742870 
 Jerry Randall, Chief Executive 
  Officer 
 James Hunter, Chief Financial 
  Officer 
 
 Panmure Gordon (UK) Limited (Nominated                            +44 (0) 20 7886 
  Adviser and Broker)                                                         2500 
 Freddy Crossley/Peter Steel/Duncan 
  Monteith (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR                                           venturelife@walbrookpr.com 
                                                        or 
                                                        +44 (0) 20 7933 8780 
                                                                  +44 (0) 7980 541 
 Paul McManus                                                                  994 
                                                                  +44 (0) 7876 741 
 Anna Dunphy                                                                   001

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREQLFBQKFXBBV

(END) Dow Jones Newswires

September 07, 2016 02:01 ET (06:01 GMT)

Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Venture Life Charts.
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Venture Life Charts.